Skip to main content
SpringerLink
Log in

Nierenzellkarzinom: Was gibt es Neues im Jahr 2010?

Renal cell carcinoma: what is new in 2010?

  • Übersichten
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

In dieser Übersicht werden neue Erkenntnisse zum Nierenzellkarzinom (NZK) dargestellt. Die Suche nach neuen Zielstrukturen der Target-Therapie sowie diagnostischen und prognostischen Markern bleibt nach wie vor ein begehrtes Forschungsgebiet. Es wird der Einsatz sowohl bereits etablierter als auch neuer Therapeutika beim metastasierten NZK (mNZK) sowie die immer großzügiger gestellte Indikation zur organerhaltenden Nierentumorchirurgie untersucht. Das Ansprechen auf die systemische Therapie beim mNZK wird weiterhin auch in definierten Subpopulationen evaluiert.

Abstract

This overview presents new insights into renal cell carcinoma (RCC). The search for new target structures for targeted therapy as well as diagnostic and prognostic markers continues to remain a desirable area of research. Investigations are focusing on the use of well-established and new therapeutic agents for metastatic RCC and an increasingly liberal indication for organ-sparing surgery for renal tumors. The response to systemic treatment in metastatic RCC is also being evaluated in defined subpopulations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Morrissey JJ, London AN, Luo J et al (2010) Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin Proc 85:413–421

    Article  PubMed  CAS  Google Scholar 

  2. Lane BR, Abouassaly R, Gao T et al (2010) Active treatment of localized renal tumors may not impact overall survival in patients aged 75 yrs or older. Cancer 116:3119–3126

    Article  PubMed  Google Scholar 

  3. Roos FC, Brenner W, Müller M et al (2010) Oncologic long-term outcome of elective nephron-sparing surgery versus radical nephrectomy in patients with renal cell carcinoma stage pt1b or greater in a matched-pair cohort. Urology 77:803–808

    Article  PubMed  Google Scholar 

  4. Van Poppel H, Da Pozzo L, Albrecht W et al (2010) A prospective randomized EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 59:543–552

    Google Scholar 

  5. Weight CJ, Lythgoe C, Unnikrishnan R et al (2010) Partial nephrectomy does not compromise survival in patients with pathologic upstaging to pT2/pT3 or high-grade renal tumors compared with radical nephrectomy. Urology 77:1142–1146

    Article  Google Scholar 

  6. Weight CJ, Lieser G, Larson BT et al (2010) Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol 58:293–298

    Article  PubMed  Google Scholar 

  7. Simone G, Papalia R, Guaglianone S et al (2010) Long term experience with laparoscopic partial nephrectomy following superselective transarterial embolization. EAU Congress 2010

  8. Lohse CM, Thompson RH, Lane BR et al (2010) Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol 58:331–336

    Article  PubMed  Google Scholar 

  9. Abel EJ, Culp SH, Meissner M et al (2010) Identifying the risk of disease progression after surgery for localized renal cell carcinoma. BJU Int 106:1277–1283

    Article  PubMed  Google Scholar 

  10. Gore ME, Griffin CL, Hancock B et al (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375:641–648

    Article  PubMed  CAS  Google Scholar 

  11. Bellmunt J, Trigo JM, Calvo E et al (2010) Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic, renal-cell carcinoma: a phase 2 study (SOGUG-02–06). Lancet Oncol 11:350–357

    Article  PubMed  CAS  Google Scholar 

  12. Zama IN, Hutson TE, Elson P et al (2010) Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116:5400–5406

    Article  PubMed  CAS  Google Scholar 

  13. Escudier B, Bellmunt J, Ne’grier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144–2150

    Article  PubMed  CAS  Google Scholar 

  14. Rini Bl, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28:2137–2143

    Article  PubMed  CAS  Google Scholar 

  15. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265

    Article  PubMed  CAS  Google Scholar 

  16. Sternberg C, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068

    Article  PubMed  CAS  Google Scholar 

  17. Malouf GG, Camparo P, Oudard S et al (2010) Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 21:1834–1838

    Article  PubMed  CAS  Google Scholar 

  18. Khan G, Golshayan A, Elson P et al (2010) Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 21:1618–1622

    Article  PubMed  CAS  Google Scholar 

  19. Yang S, Souza P de, Alemao E et al (2010) Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-a. Br J Cancer 102:1456–1460

    Article  PubMed  CAS  Google Scholar 

  20. Minamimoto R, Nakaigawa N, Tateishi U et al (2010) Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl Med 35:918–923

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinik, Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland

    I. Tsaur & A. Haferkamp

Authors
  1. I. Tsaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Haferkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Tsaur.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsaur, I., Haferkamp, A. Nierenzellkarzinom: Was gibt es Neues im Jahr 2010?. Urologe 50 (Suppl 1), 216 (2011). https://doi.org/10.1007/s00120-011-2676-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s00120-011-2676-6

Schlüsselwörter

Keywords

Search

Navigation